2011
DOI: 10.1017/s1047951111000990
|View full text |Cite
|
Sign up to set email alerts
|

Chronic hypobaric hypoxia, patent arterial duct and a new interventional technique to close it

Abstract: We conclude that the "Nit-Occlud® PDA-R" device is safe and effective in closing patent arterial duct up to a diameter of 8 millimetres.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
4
0

Year Published

2015
2015
2021
2021

Publication Types

Select...
3
2

Relationship

1
4

Authors

Journals

citations
Cited by 6 publications
(4 citation statements)
references
References 16 publications
(29 reference statements)
0
4
0
Order By: Relevance
“…Details of this device have already been described . Briefly, the Nit‐Occlud ® PDA‐R consists of a one‐piece 0.006 inch nitinol wire mesh with very low radial force (9 N, 30% lower than the Amplatzer Duct Occluder), making it less traumatic and superelastic.…”
Section: Methodsmentioning
confidence: 99%
“…Details of this device have already been described . Briefly, the Nit‐Occlud ® PDA‐R consists of a one‐piece 0.006 inch nitinol wire mesh with very low radial force (9 N, 30% lower than the Amplatzer Duct Occluder), making it less traumatic and superelastic.…”
Section: Methodsmentioning
confidence: 99%
“…A new device specifically designed to close large PDAs is the Nit‐Occlud PDA‐R® device (PFM Medical AG, Cologne, Germany). First reports have been published by Freudenthal et al in 2012 : 88 patients with very large PDAs from Bolivia, living at high altitude, were successfully treated with this new device. The initial clinical trial with this occluder published so far accepted only children with a body weight greater than 10 kg.…”
Section: Introductionmentioning
confidence: 99%
“…Early experience with the devices suggest excellent clinical outcomes with few or no complications. [2][3][4][5][6] The devices are easy to deploy, which minimizes procedure time and child exposure to imaging radiation, and their elasticity makes them minimally traumatic to friable vessels and structures of young children. They are approved by regulatory authorities in Canada, the European Union, and South America for routine use in the closure of clinically significant atrial septal defects and patent ductus arteriosus in children and adults, and we continue to develop the devices and techniques in hopes that children in other areas of the world, including perhaps one day the United States, may have them as treatment options.…”
mentioning
confidence: 99%
“…Early experience with the devices suggest excellent clinical outcomes with few or no complications . The devices are easy to deploy, which minimizes procedure time and child exposure to imaging radiation, and their elasticity makes them minimally traumatic to friable vessels and structures of young children.…”
mentioning
confidence: 99%